Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Draximage MAA Market Expansion Outlook: What Revenue Opportunities Lie Ahead?
The expansion observed in the historical timeframe was driven by the widespread presence of lung conditions, the use of nuclear imaging methods, growth in hospital diagnostic capabilities, demand for accurate pulmonary evaluation, and improvements in radiotracer development.
The expansion observed during the forecast period is driven by the increasing burden of respiratory diseases, the growth of diagnostic imaging facilities, enhancements in gamma camera technology, a stronger emphasis on early detection, and rising investments in healthcare. Key developments shaping this period include the growing adoption of nuclear medicine imaging, the broadening scope of lung function diagnostic tools, heightened demand for V/Q scans, progress in radiopharmaceutical development, and the reinforcement of imaging capabilities within hospitals.
Download A Free Sample Report For Comprehensive Market Insights:
Draximage MAA Market Development Factors: Which Trends Are Supporting Demand?
The projected rise in lung cancer cases is anticipated to drive expansion within the draximage MAA market in the coming years. Lung cancer originates in the lungs and is characterized by abnormal, uncontrolled cell proliferation that can metastasize to other parts of the body. Its increasing prevalence stems from multiple contributing factors, such as ongoing high rates of smoking, exposure to environmental contaminants like air pollution and secondhand smoke, occupational risks including asbestos and radon, and a growing elderly demographic. Draximage MAA plays a role in lung cancer management as a radiopharmaceutical utilized in positron emission tomography (PET) imaging to aid in diagnosis, staging, and treatment response monitoring, facilitating more precise evaluations and enhancing patient care strategies. For example, data from the American Cancer Society, a US-based nonprofit, published in January 2024, indicated approximately 234,580 new lung cancer diagnoses in the U.S., comprising 116,310 men and 118,270 women, alongside 125,070 deaths, with 65,790 men and 59,280 women affected, underscoring a marginally higher incidence among women but greater death rates in men. Consequently, the escalating occurrence of lung cancer is fueling growth in the draximage MAA market.
The increasing need for medical imaging is expected to drive forward the draximage MAA market in the near future. Medical imaging encompasses techniques that generate visual representations of internal body structures for diagnostic and therapeutic applications. This demand is being propelled by factors like an aging population, rising chronic disease rates, enhanced healthcare infrastructure, and a growing preference for minimally invasive approaches. Draximage MAA contributes to medical imaging by offering a radiopharmaceutical employed in scintigraphy to visualize and evaluate pulmonary function, boosting imaging precision for identifying issues such as pulmonary embolisms and assessing lung disorders, thereby supporting more accurate diagnoses and treatment planning. In May 2023, the National Health Service, a UK governmental body, reported that magnetic resonance imaging (MRI) referrals from general practitioners climbed from 8,695 in January 2022 to 8,745 in January 2023. Additionally, the same source noted that 43.4 million imaging tests were documented in England over the twelve months from February 2022 to January 2023. Hence, the heightened demand for medical imaging is propelling expansion in the draximage MAA market.
The expansion of the geriatric population is playing a pivotal role in propelling the draximage MAA market forward in the years ahead. The geriatric population includes individuals typically aged 65 and older, often regarded as being in the latter stages of life. This demographic segment is enlarging due to worldwide population aging, enhanced healthcare services, and medical treatment advancements that have lengthened life expectancy. Draximage MAA benefits older adults by serving as a radiopharmaceutical in medical imaging to accurately assess pulmonary function, identify conditions such as pulmonary embolisms, and monitor respiratory health, a critical function for seniors with multiple comorbidities who rely on accurate diagnoses for effective treatment plans. According to the Population Reference Bureau, a Kenya-based nonprofit, in January 2024, the number of Americans aged 65 and above is forecast to increase from 58 million in 2022 to 82 million by 2050, representing a 47% rise. The proportion of this age group within the total population is also predicted to grow from 17% to 23% over the same timeframe. As a result, the rising geriatric population is fostering growth in the draximage MAA market.
Draximage MAA Market Segmentation And Category Breakdown
The draximage maa market covered in this report is segmented –
1) By Indication: Lymphatic Mapping, Sentinel Lymph Node Biopsy
2) By Distribution Channel: Hospital Pharmacies, Radiopharmacy Services, Outpatient Surgical Centers
3) By End-User: Hospitals, Clinics, Ambulatory Care, Home Care
Draximage MAA Market Competitive Analysis Of Major Industry Participants
Major companies operating in the draximage maa market are Jubilant Draximage Inc.
Access The Complete Draximage MAA Market Report:
Draximage MAA Market Largest Region By Revenue And Market Share
North America was the largest region in the draximage MAA market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the draximage maa market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model